Company Plans to Seek Priority Review Voucher for Tafenoquine by Q1 2028
SXTP is trading near its 52-week low of $1.29 (12% above the low).
Summary
60 Degrees Pharmaceuticals announced its intent to pursue a valuable Priority Review Voucher for its tafenoquine drug, dependent on future trial success and FDA submission by Q1 2028.
Key Events · Product Development and Regulatory · SXTP
-
Intent to Seek Priority Review Voucher
The company plans to apply for a Commissioner's National Priority Review Voucher (PRV) for tafenoquine, pending successful clinical trial results and a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) by Q1 2028.
-
Potential Future Asset
A PRV, if obtained, could be a highly valuable asset, offering expedited FDA review for a future drug and potentially generating significant non-dilutive capital for the company.
-
Conditional and Long-Term
The application for the PRV is contingent on the outcome of ongoing clinical trials for tafenoquine in severe babesiosis and a subsequent NDA submission, making it a conditional and long-term prospect.
Analysis · SXTP · Life Sciences
60 Degrees Pharmaceuticals has outlined its intention to apply for a Commissioner's National Priority Review Voucher (PRV) for tafenoquine, contingent on successful clinical trial outcomes and a New Drug Application (NDA) submission to the FDA by the first quarter of 2028. While highly conditional and long-term, a PRV can be a significant asset, potentially worth hundreds of millions, for a company with a market capitalization of only $3.86 million. This disclosure provides investors with insight into a major potential value driver for the company's pipeline, despite its current critical cash runway and going concern issues.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 30.2% of the 1943 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SXTP was trading at $1.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9M. The 52-week trading range was $1.29 to $14.68. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.